Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
2.
Int J Lab Hematol ; 43(6): 1309-1318, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1409690

ABSTRACT

INTRODUCTION: Developing prognostic markers can be useful for clinical decision-making. Peripheral blood (PB) examination is simple and basic that can be performed in any facility. We aimed to investigate whether PB examination can predict prognosis in coronavirus disease (COVID-19). METHODS: Complete blood count (CBC) and PB cell morphology were examined in 38 healthy controls (HCs) and 40 patients with COVID-19. Patients with COVID-19, including 26 mild and 14 severe cases, were hospitalized in Juntendo University Hospital (Tokyo, Japan) between April 1 and August 6, 2020. PB examinations were performed using Sysmex XN-3000 automated hematology analyzer and Sysmex DI-60 employing the convolutional neural network-based automatic image-recognition system. RESULTS: Compared with mild cases, severe cases showed a significantly higher incidence of anemia, lymphopenia, and leukocytosis (P < .001). Granular lymphocyte counts were normal or higher in mild cases and persistently decreased in fatal cases. Temporary increase in granular lymphocytes was associated with survival of patients with severe infection. Red cell distribution width was significantly higher in severe cases than in mild cases (P < .001). Neutrophil dysplasia was consistently observed in COVID-19 cases, but not in HCs. Levels of giant neutrophils and toxic granulation/Döhle bodies were increased in severe cases. CONCLUSION: Basic PB examination can be useful to predict the prognosis of COVID-19, by detecting SARS-CoV-2 infection-induced multi-lineage changes in blood cell counts and morphological anomalies. These changes were dynamically correlated with disease severity and may be associated with disruption of hematopoiesis and the immunological system due to bone marrow stress in severe infection.


Subject(s)
Blood Cell Count , COVID-19/blood , Leukocytosis/etiology , Lymphocytes/ultrastructure , Lymphopenia/etiology , Neutrophils/ultrastructure , SARS-CoV-2 , Aged , Anemia/blood , Anemia/etiology , Blood Cell Count/instrumentation , Blood Cell Count/methods , COVID-19/mortality , Cell Shape , Cytoplasmic Granules/ultrastructure , Erythrocyte Indices , Female , Humans , Image Processing, Computer-Assisted , Leukocytosis/blood , Lymphocyte Count , Lymphopenia/blood , Male , Middle Aged , Neural Networks, Computer , Prognosis , Severity of Illness Index
3.
Pharmacol Res ; 160: 105036, 2020 10.
Article in English | MEDLINE | ID: covidwho-1364401

ABSTRACT

OBJECTIVES: The current diagnosis and medicines approach in coronavirus disease 2019 (COVID-19) does not reflect the heterogeneous characteristics of this disease. This study aims to find a new antiviral combination regimen by investigating the frequency of clinically relevant and objectively identified comorbidities, and the clustering of these clinical syndromes and varying results of treatment with antiviral drugs in patients hospitalized with severe COVID-19. METHODS: This study recruited 151 severe COVID-19 infection cases diagnosed in our hospital examination and illustrated the clinical potential during a consecutive 25-day medication period. Potential differences in disease severity and clinical characteristics, hematological profile, and current pharmacologic treatments (single agent, double or triple combinations, and the combined antiviral drugs plus Lianhua Qingwen) among comorbidity clusters were explored. RESULTS: Although disease severity was comparable among three clusters, it was markedly different in terms of laboratory test status. Coagulable abnormality was mainly present in cluster 1 and cluster 2. Other indicators were normal, except for a significant increase of neutrophils presented in cluster 2. Patients showed the most complicated haematological results in cluster 3, including severe coagulation abnormalities, leukocytosis, neutrophilic granulocytosis, and lymphopenia. Our results for the first time suggest that a quadruple combination therapy (Ribavirin, Lopinavir/ritonavir, Umifenovir, and Lianhua Qingwen) can be considered as a preferred treatment approach to severe COVID-19 patients. After treatment, abnormal coagulation and leukocyte had markedly improved with a better prognosis. CONCLUSION: This study expands the understanding of the co-occurrence of combination therapy in patients with COVID-19, which provides the probability of developing novel combined therapy. Furthermore, explore clinical trials of variable antivirus treatments based on subgroup analyses or on using subgroups in the selection criteria would be the next step.


Subject(s)
Antiviral Agents/therapeutic use , Coronavirus Infections/blood , Coronavirus Infections/drug therapy , Pneumonia, Viral/blood , Pneumonia, Viral/drug therapy , Adult , Aged , Blood Cell Count , Blood Coagulation , COVID-19 , Comorbidity , Drug Therapy, Combination , Female , Granulocytes , Humans , Leukocyte Count , Leukocytosis/etiology , Lymphopenia/etiology , Male , Middle Aged , Pandemics , Treatment Outcome , COVID-19 Drug Treatment
4.
J Investig Med High Impact Case Rep ; 9: 23247096211024773, 2021.
Article in English | MEDLINE | ID: covidwho-1270925

ABSTRACT

The gastrointestinal (GI) involvement, including acute pancreatitis (AP) from the novel coronavirus disease-2019 (COVID-19), is increasingly being reported. Recent evidence suggests that the pathogenesis of COVID-19 is mediated by the angiotensin-converting enzyme 2 (ACE-2) receptors and transmembrane protease serine 2 (TMPRSS2) for "priming," which is highly expressed in the pancreas. To our knowledge, there is no other reported case of AP associated with COVID-19 after the respiratory symptoms are resolved. In this article, we present a patient with COVID-19, who came with intractable epigastric pain and resolved respiratory symptoms. A diagnosis of AP complicated with COVID-19 was made after laboratory and imaging workup, which was successfully managed conservatively.


Subject(s)
COVID-19/diagnosis , Pancreatitis/diagnosis , Abdominal Pain/etiology , Anti-Bacterial Agents/therapeutic use , Humans , Leukocytosis/etiology , Lipase/blood , Male , Pancreatitis/therapy , Piperacillin, Tazobactam Drug Combination/therapeutic use , Tomography, X-Ray Computed , Young Adult
5.
Front Immunol ; 12: 645741, 2021.
Article in English | MEDLINE | ID: covidwho-1190313

ABSTRACT

Particulate matter (PM) induces neutrophilic inflammation and deteriorates the prognosis of diseases such as cardiovascular diseases, cancers, and infections, including COVID-19. Here, we addressed the role of γδ T cells and intestinal microbiome in PM-induced acute neutrophilia. γδ T cells are a heterogeneous population composed of Tγδ1, Tγδ2, Tγδ17, and naïve γδ T cells (TγδN) and commensal bacteria promote local expansion of Tγδ17 cells, particularly in the lung and gut without affecting their Vγ repertoire. Tγδ17 cells are more tissue resident than Tγδ1 cells, while TγδN cells are circulating cells. IL-1R expression in Tγδ17 cells is highest in the lung and they outnumber all the other type 17 cells such as Th17, ILC3, NKT17, and MAIT17 cells. Upon PM exposure, IL-1ß-secreting neutrophils and IL-17-producing Tγδ17 cells attract each other around the airways. Accordingly, PM-induced neutrophilia was significantly relieved in γδ T- or IL-17-deficient and germ-free mice. Collectively, these findings show that the commensal microbiome promotes PM-induced neutrophilia in the lung via Tγδ17 cells.


Subject(s)
Leukocytosis/etiology , Lung/immunology , Microbiota , Neutrophils/pathology , Particulate Matter/adverse effects , Receptors, Antigen, T-Cell, gamma-delta/metabolism , Th17 Cells/immunology , Th17 Cells/metabolism , Animals , Asthma/etiology , Asthma/metabolism , Asthma/pathology , Biomarkers , Cytokines/metabolism , Disease Models, Animal , Disease Susceptibility , Fluorescent Antibody Technique , Immunity, Innate , Immunophenotyping , Leukocytosis/metabolism , Leukocytosis/pathology , Lung/metabolism , Lung/pathology , Mice , Neutrophils/metabolism , T-Lymphocyte Subsets/immunology , T-Lymphocyte Subsets/metabolism
6.
Emerg Infect Dis ; 27(4): 1196-1200, 2021 04.
Article in English | MEDLINE | ID: covidwho-1067635
7.
Int J Infect Dis ; 104: 390-397, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1014554

ABSTRACT

BACKGROUND: Limited literature exists on Cerebrospinal fluid (CSF) findings in COVID-19 patients with neurological symptoms. In this review, we conducted a descriptive analysis of CSF findings in patients with COVID-19 to understand prognosis and explore therapeutic options. METHODS: We searched PubMed, Google Scholar, and Scopus databases using the keywords "SARS-CoV-2 in cerebrospinal fluid" and "SARS-CoV-2 and CNS Complications"" for reports of CSF findings in COVID-19 related neurological manifestations. Descriptive analyses were conducted to observe the CSF protein and cell counts based on age, gender, severity, fatality of COVID-19, and whether central (CNS) or peripheral nervous system (PNS) was associated. RESULTS: A total of 113 patients were identified from 67 studies. Of these, 7 patients (6.2%) were fatal COVID-19 cases and 35 patients (31%) were considered severe COVID-19 cases. CSF protein was elevated in 100% (7/7) of the fatal cases with an average of 61.28 mg/dl and in 65.0% (52/80) in non-fatal cases with an average 56.73 mg/dl. CSF protein levels were elevated in 74.5% (38/51) patients with non-severe COVID-19 and 68.6% (24/35) in those with a severe COVID-19 infection. CSF cell count was increased in 43% of fatal cases, 25.7% severe cases, and 29.4% of non-severe cases. CONCLUSION: Our analysis showed that the most common CSF findings situation in COVID-19 infection is elevated protein with, very occasionally, mild lymphocyte predominant pleocytosis. Further studies to elucidate the pathophysiology of neurological complications in COVID-19 are recommended.


Subject(s)
COVID-19/cerebrospinal fluid , Leukocytosis/cerebrospinal fluid , Nervous System Diseases/cerebrospinal fluid , SARS-CoV-2/physiology , COVID-19/complications , COVID-19/virology , Humans , Leukocytosis/etiology , Nervous System Diseases/etiology
8.
Blood Purif ; 49(6): 758-760, 2020.
Article in English | MEDLINE | ID: covidwho-138996

ABSTRACT

We describe a 2 weeks corrected gestational age infant admitted in pediatric intensive care unit (PICU) for severe acute respiratory distress syndrome (ARDS) associated to Bordetella pertussis and Coronavirus infection. He developed leukocytosis as soon as ARDS required intubation and aggressive mechanical ventilation: hence he underwent 3 early therapeutic leukapheresis treatments in order to avoid the worsening of related cardiopulmonary complications, according to recent literature on pertussis infection in infants. The infant was discharged from PICU healthy.


Subject(s)
Bordetella pertussis/isolation & purification , Coinfection/complications , Coronavirus Infections/complications , Coronavirus/isolation & purification , Leukapheresis , Leukocytosis/therapy , Respiratory Distress Syndrome, Newborn/etiology , Whooping Cough/complications , Coinfection/blood , Coinfection/microbiology , Coinfection/virology , Combined Modality Therapy , Continuous Positive Airway Pressure , Coronavirus Infections/blood , Coronavirus Infections/virology , Humans , Infant , Leukocytosis/etiology , Male , Respiration, Artificial , Respiratory Distress Syndrome, Newborn/blood , Respiratory Distress Syndrome, Newborn/therapy , Whooping Cough/blood
SELECTION OF CITATIONS
SEARCH DETAIL